These observations may explain why the synergy of FGFR and PLK1 inhibitors observed in KRAS‐mutant lung and pancreatic cancer cells does not translate to KRAS‐mutant colon cancer cells. The gene discussed is KRAS; the disease is malignant colon neoplasm.